Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine
We assessed whether the impact of cabotegravir plus rilpivirine on inflammation reduction differs from that of oral antiretrovirals, using real-world data. Inflammatory biomarkers and lipid profiles were followed from baseline to 8 months after switching. Seventy-eight participants were analyzed. Th...
Saved in:
| Published in | AIDS research and therapy Vol. 21; no. 1; pp. 1 - 6 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
03.01.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | We assessed whether the impact of cabotegravir plus rilpivirine on inflammation reduction differs from that of oral antiretrovirals, using real-world data. Inflammatory biomarkers and lipid profiles were followed from baseline to 8 months after switching. Seventy-eight participants were analyzed. The CD4/CD8 ratio and C-reactive protein did not change. There were transient decreases in CD8 and CD4 counts in the group that switched from the dolutegravir-based regimen, but not in the tenofovir alafenamide-based regimen group. High-density lipoprotein (HDL) cholesterol increased, resulting in a decrease in the total-cholesterol to HDL cholesterol ratio, whereas there was no significant change in low-density lipoprotein cholesterol. |
|---|---|
| AbstractList | We assessed whether the impact of cabotegravir plus rilpivirine on inflammation reduction differs from that of oral antiretrovirals, using real-world data. Inflammatory biomarkers and lipid profiles were followed from baseline to 8 months after switching. Seventy-eight participants were analyzed. The CD4/CD8 ratio and C-reactive protein did not change. There were transient decreases in CD8 and CD4 counts in the group that switched from the dolutegravir-based regimen, but not in the tenofovir alafenamide-based regimen group. High-density lipoprotein (HDL) cholesterol increased, resulting in a decrease in the total-cholesterol to HDL cholesterol ratio, whereas there was no significant change in low-density lipoprotein cholesterol. We assessed whether the impact of cabotegravir plus rilpivirine on inflammation reduction differs from that of oral antiretrovirals, using real-world data. Inflammatory biomarkers and lipid profiles were followed from baseline to 8 months after switching. Seventy-eight participants were analyzed. The CD4/CD8 ratio and C-reactive protein did not change. There were transient decreases in CD8 and CD4 counts in the group that switched from the dolutegravir-based regimen, but not in the tenofovir alafenamide-based regimen group. High-density lipoprotein (HDL) cholesterol increased, resulting in a decrease in the total-cholesterol to HDL cholesterol ratio, whereas there was no significant change in low-density lipoprotein cholesterol.We assessed whether the impact of cabotegravir plus rilpivirine on inflammation reduction differs from that of oral antiretrovirals, using real-world data. Inflammatory biomarkers and lipid profiles were followed from baseline to 8 months after switching. Seventy-eight participants were analyzed. The CD4/CD8 ratio and C-reactive protein did not change. There were transient decreases in CD8 and CD4 counts in the group that switched from the dolutegravir-based regimen, but not in the tenofovir alafenamide-based regimen group. High-density lipoprotein (HDL) cholesterol increased, resulting in a decrease in the total-cholesterol to HDL cholesterol ratio, whereas there was no significant change in low-density lipoprotein cholesterol. Abstract We assessed whether the impact of cabotegravir plus rilpivirine on inflammation reduction differs from that of oral antiretrovirals, using real-world data. Inflammatory biomarkers and lipid profiles were followed from baseline to 8 months after switching. Seventy-eight participants were analyzed. The CD4/CD8 ratio and C-reactive protein did not change. There were transient decreases in CD8 and CD4 counts in the group that switched from the dolutegravir-based regimen, but not in the tenofovir alafenamide-based regimen group. High-density lipoprotein (HDL) cholesterol increased, resulting in a decrease in the total-cholesterol to HDL cholesterol ratio, whereas there was no significant change in low-density lipoprotein cholesterol. We assessed whether the impact of cabotegravir plus rilpivirine on inflammation reduction differs from that of oral antiretrovirals, using real-world data. Inflammatory biomarkers and lipid profiles were followed from baseline to 8 months after switching. Seventy-eight participants were analyzed. The CD4/CD8 ratio and C-reactive protein did not change. There were transient decreases in CD8 and CD4 counts in the group that switched from the dolutegravir-based regimen, but not in the tenofovir alafenamide-based regimen group. High-density lipoprotein (HDL) cholesterol increased, resulting in a decrease in the total-cholesterol to HDL cholesterol ratio, whereas there was no significant change in low-density lipoprotein cholesterol. Keywords: Cabotegravir plus rilpivirine, Inflammatory biomarker, Lipid profile, HIV, Long-acting drug |
| ArticleNumber | 1 |
| Audience | Academic |
| Author | Koga, Michiko Saito, Makoto Yotsuyanagi, Hiroshi Otani, Amato Adachi, Eisuke |
| Author_xml | – sequence: 1 givenname: Eisuke surname: Adachi fullname: Adachi, Eisuke – sequence: 2 givenname: Makoto surname: Saito fullname: Saito, Makoto – sequence: 3 givenname: Amato surname: Otani fullname: Otani, Amato – sequence: 4 givenname: Michiko surname: Koga fullname: Koga, Michiko – sequence: 5 givenname: Hiroshi surname: Yotsuyanagi fullname: Yotsuyanagi, Hiroshi |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38173008$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9k9tu1DAQhiNURA_wAlygSEgILlJ8ip1wg0rFYUUluIBra-I4WRfHXmyn0DfgsfHulrJbIWTLx29-a8Yzx8WB804XxWOMTjFu-MuISdvgChFaIVS3qGL3iiMsGKk4Q_XBzvqwOI7xEiHKCa4fFIe0wYIi1BwVv94Eo4dS-WmanVGQjHfxVamW4EYdS-NyHyxMEyQfrsvO-AnCNx1iCa4vrVmZvlwFPxibaRiSDmX8YZJaGjeWyZfWu7ECldZbBZ1PegxwZUK5snMsg7Erk3fG6YfF_QFs1I9u5pPi67u3X84_VBef3i_Ozy4qxds6VW0DILqWtUCZFlQAF13XIN13Ne9rynpBatTyhtOe15rzTnDSQc062nYMC05PisVWt_dwKVfBZH-upQcjNwc-jBJCMspqmYPbDJqKphE9Gwh0GPJa5wFhxQBnrddbrdXcTbpX2qUAdk90_8aZpRz9lcRI8LplNCs8v1EI_vusY5KTiUpbC077OUrSYoRbTlmd0ad30Es_B5djtaYYEQJj_pcaIXuQ_87nh9VaVJ4J0RBMCGeZOv0HlVuvJ6Nylq3_c9_gxZ5BZpL-mUaYY5QfPy_22Wc77FKDTcvo7bxJrX3wyW74buP2JzszQLaACj7GoIdbBCO5LgG5LQGZS0BuSkCuVZs7RsqkTV5nH439n-lvPWoJiQ |
| CitedBy_id | crossref_primary_10_3390_life14040449 crossref_primary_10_1093_jac_dkaf025 crossref_primary_10_1007_s10461_024_04597_4 |
| Cites_doi | 10.1371/journal.pmed.0050203 10.1093/cid/ciw650 10.1016/j.jmii.2020.09.005 10.1093/ofid/ofac068 10.1056/NEJMoa1904398 10.1097/QAD.0000000000000675 10.1056/NEJMoa2101016 10.1016/j.immuni.2013.10.001 10.1007/s11904-020-00509-y 10.1093/ofid/ofx262 10.1093/infdis/jiu132 10.1093/cid/ciad020 10.1089/aid.2022.0115 10.1371/journal.ppat.1004078 10.1016/S2352-3018(17)30068-1 10.4049/jimmunol.176.4.2645 10.1056/NEJMe078029 10.1016/j.jiac.2022.09.008 10.1093/cid/civ296 10.1016/S2352-3018(21)00184-3 |
| ContentType | Journal Article |
| Copyright | 2023. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 |
| Copyright_xml | – notice: 2023. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM KPI 3V. 7T2 7T5 7U9 7X7 7XB 88E 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12981-023-00590-4 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Global Issues ProQuest Central (Corporate) Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni) Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection Environmental Sciences and Pollution Management ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1742-6405 |
| EndPage | 6 |
| ExternalDocumentID | oai_doaj_org_article_9818fe37887d4f2ab1a788ea7801c4a1 PMC10765943 A778212264 38173008 10_1186_s12981_023_00590_4 |
| Genre | Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GroupedDBID | --- 0R~ 23M 2WC 53G 5GY 5VS 6J9 7X7 88E 8C1 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACPRK ACUHS ADBBV ADRAZ ADUKV AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR IHW INH INR ITC KPI KQ8 LK8 M1P M48 M7P M~E N8Y O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB PMFND 3V. 7T2 7T5 7U9 7XB 8FK AZQEC C1K DWQXO GNUQQ H94 K9. PKEHL PQEST PQUKI 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c695t-98aa7b949a34e737a67bb80edb56d534d725096863d65e66b762ba54b39b41763 |
| IEDL.DBID | M48 |
| ISSN | 1742-6405 |
| IngestDate | Wed Aug 27 01:31:38 EDT 2025 Thu Aug 21 18:42:17 EDT 2025 Mon Jul 21 10:01:21 EDT 2025 Fri Jul 25 19:07:25 EDT 2025 Tue Jun 17 22:27:31 EDT 2025 Tue Jun 10 21:15:57 EDT 2025 Fri Jun 27 05:36:06 EDT 2025 Thu May 22 21:06:09 EDT 2025 Mon Jul 21 06:02:36 EDT 2025 Tue Jul 01 04:09:56 EDT 2025 Thu Apr 24 23:11:15 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Cabotegravir plus rilpivirine Lipid profile Long-acting drug HIV Inflammatory biomarker |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c695t-98aa7b949a34e737a67bb80edb56d534d725096863d65e66b762ba54b39b41763 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12981-023-00590-4 |
| PMID | 38173008 |
| PQID | 2914277116 |
| PQPubID | 55039 |
| PageCount | 6 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9818fe37887d4f2ab1a788ea7801c4a1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10765943 proquest_miscellaneous_2910196345 proquest_journals_2914277116 gale_infotracmisc_A778212264 gale_infotracacademiconefile_A778212264 gale_incontextgauss_KPI_A778212264 gale_healthsolutions_A778212264 pubmed_primary_38173008 crossref_primary_10_1186_s12981_023_00590_4 crossref_citationtrail_10_1186_s12981_023_00590_4 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-01-03 |
| PublicationDateYYYYMMDD | 2024-01-03 |
| PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-03 day: 03 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | AIDS research and therapy |
| PublicationTitleAlternate | AIDS Res Ther |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | LA Ramirez (590_CR8) 2014; 210 A Kettelhut (590_CR4) 2020; 17 JV Baker (590_CR6) 2017; 4 E Adachi (590_CR10) 2022; 38 E Adachi (590_CR13) 2023; 29 S Serrano-Villar (590_CR17) 2014; 10 E Hamlyn (590_CR5) 2015; 29 SG Deeks (590_CR3) 2013; 39 JR Santos (590_CR18) 2015; 61 S Swindells (590_CR20) 2020; 382 LH Kuller (590_CR1) 2008; 5 RJ Landovitz (590_CR15) 2021; 385 C Orkin (590_CR11) 2021; 8 AR Tall (590_CR19) 2007; 356 M Markowitz (590_CR14) 2017; 4 JR Castillo-Mancilla (590_CR2) 2016; 63 S Yamamoto (590_CR7) 2021; 54 ET Overton (590_CR12) 2023; 76 JM Llibre (590_CR9) 2022; 9 SR Hadrup (590_CR16) 2006; 176 |
| References_xml | – volume: 5 start-page: e203 issue: 10 year: 2008 ident: 590_CR1 publication-title: PLoS Med doi: 10.1371/journal.pmed.0050203 – volume: 63 start-page: 1661 issue: 12 year: 2016 ident: 590_CR2 publication-title: Clin Infect Dis doi: 10.1093/cid/ciw650 – volume: 54 start-page: 144 issue: 1 year: 2021 ident: 590_CR7 publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2020.09.005 – volume: 9 start-page: ofac068 issue: 4 year: 2022 ident: 590_CR9 publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofac068 – volume: 382 start-page: 1112 issue: 12 year: 2020 ident: 590_CR20 publication-title: N Engl J Med doi: 10.1056/NEJMoa1904398 – volume: 29 start-page: 1355 issue: 11 year: 2015 ident: 590_CR5 publication-title: Aids doi: 10.1097/QAD.0000000000000675 – volume: 385 start-page: 595 issue: 7 year: 2021 ident: 590_CR15 publication-title: N Engl J Med doi: 10.1056/NEJMoa2101016 – volume: 39 start-page: 633 issue: 4 year: 2013 ident: 590_CR3 publication-title: Immunity doi: 10.1016/j.immuni.2013.10.001 – volume: 17 start-page: 394 issue: 4 year: 2020 ident: 590_CR4 publication-title: Curr HIV/AIDS Rep doi: 10.1007/s11904-020-00509-y – volume: 4 start-page: ofx262 issue: 4 year: 2017 ident: 590_CR6 publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofx262 – volume: 210 start-page: 646 issue: 4 year: 2014 ident: 590_CR8 publication-title: J Infect Dis doi: 10.1093/infdis/jiu132 – volume: 76 start-page: 1646 issue: 9 year: 2023 ident: 590_CR12 publication-title: Clin Infect Dis doi: 10.1093/cid/ciad020 – volume: 38 start-page: 881 issue: 12 year: 2022 ident: 590_CR10 publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2022.0115 – volume: 10 start-page: e1004078 issue: 5 year: 2014 ident: 590_CR17 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1004078 – volume: 4 start-page: e331 issue: 8 year: 2017 ident: 590_CR14 publication-title: Lancet HIV doi: 10.1016/S2352-3018(17)30068-1 – volume: 176 start-page: 2645 issue: 4 year: 2006 ident: 590_CR16 publication-title: J Immunol doi: 10.4049/jimmunol.176.4.2645 – volume: 356 start-page: 1364 issue: 13 year: 2007 ident: 590_CR19 publication-title: N Engl J Med doi: 10.1056/NEJMe078029 – volume: 29 start-page: 109 issue: 1 year: 2023 ident: 590_CR13 publication-title: J Infect Chemother doi: 10.1016/j.jiac.2022.09.008 – volume: 61 start-page: 403 issue: 3 year: 2015 ident: 590_CR18 publication-title: Clin Infect Dis doi: 10.1093/cid/civ296 – volume: 8 start-page: e668 issue: 11 year: 2021 ident: 590_CR11 publication-title: Lancet HIV doi: 10.1016/S2352-3018(21)00184-3 |
| SSID | ssj0036215 |
| Score | 2.3464606 |
| Snippet | We assessed whether the impact of cabotegravir plus rilpivirine on inflammation reduction differs from that of oral antiretrovirals, using real-world data.... Abstract We assessed whether the impact of cabotegravir plus rilpivirine on inflammation reduction differs from that of oral antiretrovirals, using real-world... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1 |
| SubjectTerms | Acquired immune deficiency syndrome AIDS Analysis Analysis and chemistry Anti-HIV Agents - therapeutic use Anti-Retroviral Agents - therapeutic use Antiretroviral drugs Antiviral agents Biological markers Biomarkers Blood Blood cholesterol C-reactive protein Cabotegravir plus rilpivirine CD4 antigen CD8 antigen Cholesterol Cholesterol - therapeutic use Clinical medicine Clinical trials Density Dosage and administration Drug dosages Health aspects High density lipoprotein HIV HIV Infections - drug therapy Human immunodeficiency virus Humans Inflammation Inflammatory biomarker Inflammatory diseases Lipid profile Lipids Long-acting drug Low density lipoproteins Measurement Raltegravir Rilpivirine Rilpivirine - therapeutic use Switching Tenofovir Variance analysis |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yDyKI6PlVPTWK4IOU2zRp0vh2isepnPjgwb2FpGnPQm2XbVf_Bf9sZ5Ju2SLoi7As22ZaupnpfLTz-4WQl557WxRCpNK6IhWOuVRbx9IaMjmeSy2cQnDy-Wd5diE-XuaXe0t9YU9YpAeOE3esIaLUFbKeKy_qDM5j4XcFXytWChsKH4h5u2Iq-mDwyizfQWQKeTxAVCugbM54GtCWqViEocDW_6dP3gtKy4bJvQh0epvcmlJHehIv-Q65VnWH5Pr59HL8kNyMj-BoRBbdJb-g8K9qWu5DQIY3NEJ9B9p08KnBIL6HF-0UgfjYq7MZqO08bZt14-m0pDfswrXE6fCzGUPzJR172vbdVYq4CNgswZYC78SPZkPX7Xagm6ZdN7AFl3aPXJy-__ruLJ0WXkhLqfMx1YW1ymmhLReV4spK5VyxqrzLpc-58CpD1phCci_zSkoHHtXZXDiunWDgse6Tg67vqoeErjRmmJC1KQulpC9tLbwsawdFubZelAlhOz2YcmIlx8UxWhOqk0KaqDsDujNBd0Yk5PV8zDpycvxV-i2qd5ZEPu2wA6zMTFZm_mVlCXmGxmEiOHX2CuZEQYbFEIyckBdBAjk1OmzaubLbYTCfvnxYCL2ahOoe_mVpJwwEzBUqcyF5tJCEm75cDu-s1ExOZzCZZiJTijGZkOfzMB6JjXRd1W-DDDIicZEn5EE06nlmkKyRQ06YkGJh7oupW450zbdASc5WSuZa8Ef_Y7IfkxsZpI7hQRc_IgfjZls9gdRvdE_DXf4b74pVRQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fi9QwEA96gggiev6rnhpF8EHKbZo0aXyRUzxO5cQHD_YtJE27FtZ23e7qV_BjO5Nm6xbhYCnbZgJtZjKZSWZ-Q8hLz70tCiFSaV2RCsdcqq1jaQ2WHM-lFk5hcvL5F3l2IT7N83nccOtjWOVOJwZF7bsS98iPM81EphRj8u3qZ4pVo_B0NZbQuEquIXQZSrWajw4X6GaW7xJlCnncw9pWgPOc8TTkXKZishgFzP7_NfPe0jQNm9xbh05vk1vRgKQnA8fvkCtVe0iun8cj8kNyc9iIo0N-0V3yB9z_qqblfiJI_4YOCb89bVr41SAWP8JxO8V0fIzYWffUtp4um1XjaSzsDY-wojjtfzebEIJJNx1ddu0ixewIuC1BogL6xK9mTVfLbU_XzXLVwB282j1ycfrh2_uzNJZfSEup802qC2uV00JbLirFlZXKuWJWeZdLn3PhVYbYMYXkXuaVlA70qrO5cFw7wUBv3ScHbddWDwmdabQzwXZTFhxKX9paeFnWDlxzbb0oE8J2fDBlxCbHEhlLE3yUQpqBdwZ4ZwLvjEjI67HPakDmuJT6HbJ3pERU7fCgWy9MnKQG-hR1hQj7yos6A5m18L-Cy4yVwrKEPEPhMEOK6qgbzIkCO4thSnJCXgQKRNZoMXRnYbd9bz5__TghehWJ6g6-srQxEwLGCpk5oTyaUMLUL6fNOyk1UfX05t9EScjzsRl7YjhdW3XbQIO4SFzkCXkwCPU4MgjZyMEyTEgxEffJ0E1b2uZ7ACZnMyVzLfijy9_rMbmRgWkYNrL4ETnYrLfVEzDtNu5pmL9_AfpmTO8 priority: 102 providerName: ProQuest |
| Title | Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38173008 https://www.proquest.com/docview/2914277116 https://www.proquest.com/docview/2910196345 https://pubmed.ncbi.nlm.nih.gov/PMC10765943 https://doaj.org/article/9818fe37887d4f2ab1a788ea7801c4a1 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ri9QwEA_3gONARM9X9VyjCH6Q6rZJk1QQ2T3uOFf2ONSF-xaSPtZCbdd218d_4J_tJH2wxVNYuttmsuxmHplJ8ptB6HlMYiUEpS5TWrhUe9oNlfbcFDw5ErCQam7AyfMLdr6gs6vgagd15Y7aAayvDe1MPalFlb_6-e3XO1D4t1bhBXtdw5wlICj2iWuxlC7dRfswM3FT0WBO-10FsNVe0AFnru13iA5MxjoyNtUmt-Ypm87_b6O9NWsNT1RuTVFnt9DN1rfEk0YYbqOdpDhCB_N29_wI3WjW6HADPbqDfk8hTk5xtI0Rqd_gBgtc46yAVwoS89XuxGOD1DeHeaoaqyLGebbKYtzW_IZHptg4rn9ka3s6E69LnJfF0jXACbiNQNhsYorvWYVX-abGVZavMriDn3YXLc5OP5-cu21lBjdiYbB2Q6EU1yENFaEJJ1wxrrUYJ7EOWBwQGnPfpJURjMQsSBjTYHK1CqgmoQa-MHIP7RVlkTxAeBwaFxTcOq4g1owjldKYRamGqD1UMY0c5HV8kFGbttxUz8ilDV8Ekw0bJbBRWjZK6qCXfZ9Vk7Tjv9RTw96e0iTctg_Kailb_ZXQR6SJSb7PY5r6IM4KPidwGXsRVZ6DnhjhkA16tTcbcsLBBfMMWtlBzyyFSbpRmFM9S7Wpa_nh8v2A6EVLlJbwLyPVgiRgrAwzB5THA0qwCtGwuZNS2SmV9EOP-px7HnPQ077Z9DQn7Yqk3FgakzKJ0MBB9xuh7kem0w0HiYG4D4Zu2FJkX2zOcm_MWRBS8vCfX_oIHfrgMNrlLXKM9tbVJnkMDt9aj9Auv-JwFSfeCO1PJrNPM3ifnl5cfhzZRZSR1fM_FR1Vtw |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELfGkAAJIRj_AoMZBOIBRWtix06QENoGU0u3iYdN2pux46REKklpWia-AZ-Gz8idk4ZGSHubVFVNfI5S3_nubN_vjpBXllkdx5z7QpvY5yYwfqJN4OfgybFIJNxIBCcfn4jhGf98Hp1vkD8rLAyGVa50olPUtkpxj3w3TAIeShkE4sPsh49Vo_B0dVVCoxGLcfbrApZs9fvRR-Dv6zA8_HR6MPTbqgJ-KpJo4Sex1tIkPNGMZ5JJLaQx8SCzJhI2YtzKEFOixIJZEWVCGFAXRkfcsMTwAKYjPPcauc4ZTE1Eph90ISVgC4JoBcyJxW4NtjSGxXrIfIfx9HnP-LkaAf9bgjVT2A_TXLN7h3fJndZhpXuNhN0jG1m5RW4ct0fyW-R2s_FHGzzTffJ7HxbfOU3XgSf1O9oAjGtalPDJQQy_u-N9ivB_jBCa11SXlk6LWWFpW0gcbmEFc1pfFAsX8kkXFZ1W5cRHNAZcpiDBLtvFz2JOZ9NlTefFdFbAFbzaA3J2JYx5SDbLqsweEzpI0K8FX1FqWMDaVOfcijQ3Ihkk2vLUI8GKDyptc6FjSY6pcmuiWKiGdwp4pxzvFPfI267PrMkEcin1PrK3o8Qs3u5GNZ-oViko6BPnGWb0l5bnIcwRDb8z-BoEKdeBR3ZQOFQDie10kdqT4NcFCIH2yEtHgZk8SgwVmuhlXavxl1GP6E1LlFfwL1PdIi9grJCZPcrtHiWomrTfvJJS1aq6Wv2bmB550TVjTwzfK7Nq6WgwDxPjkUceNULdjQymiGTgiXok7ol7b-j6LWXxzSVCDwZSRAlnTy5_rx1yc3h6fKSORifjp-RWCG6p20Rj22RzMV9mz8CtXJjnbi5T8vWqlcdfrD-IKg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brief+communications%3A+changes+in+inflammatory+biomarkers+and+lipid+profiles+after+switching+to+long-acting+cabotegravir+plus+rilpivirine&rft.jtitle=AIDS+research+and+therapy&rft.au=Adachi%2C+Eisuke&rft.au=Saito%2C+Makoto&rft.au=Otani%2C+Amato&rft.au=Koga%2C+Michiko&rft.date=2024-01-03&rft.eissn=1742-6405&rft.volume=21&rft.issue=1&rft.spage=1&rft_id=info:doi/10.1186%2Fs12981-023-00590-4&rft_id=info%3Apmid%2F38173008&rft.externalDocID=38173008 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-6405&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-6405&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-6405&client=summon |